Table 2.
Model inputs for the base-case scenario in all-comers
| Parameter | CRT-P | CRT-D | Source |
|---|---|---|---|
| Infection rates up to 24 months (CRT-D), SoC | 4.14% | 4.14% | Frausing et al.15 |
| HR of infection with an envelope up to 24 months | 0.52 | 0.52 | Frausing et al.15 |
| Re-infection following no extraction | 71.40% | 71.40% | Pichlmaier et al.19 |
| Re-infection following complete extraction | 4.80% | 4.80% | Ahmed et al.3 |
| Mortality no infection | 11.00% | 11.00% | WRAP-IT8 |
| Lifetime costs without CIED | €8662 | €8662 | NICE18 |
| Lifetime costs with CIED | €20 679 | €23 107 | NICE18 |
| Lifetime QALYs without CIED | 2.78 | 2.78 | WRAP-IT8 |
| Lifetime QALYs with CIED | 3.47 | 3.88 | WRAP-IT8 |
| Baseline utility after treatment with CIED | 0.76 | 0.81 | WRAP-IT8 |
| Disutility with major CIED infection for 6 months | −0.10 | −0.10 | WRAP-IT8 |
| Infection cost no extraction, SoC | €40 765 | €50 366 | Calculated (DRGs) |
CRT-P/-D, cardiac resynchronization therapy pacemaker/-defibrillator; QALY, quality-adjusted life year; SoC, standard of care.